Advertisement

Picture EBD Group ChinaBio Partnerting Forum 2021 651x80

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in Austria, Germany and Switzerland or involving organisations from these countries.

Total search results: 3067 | Ordered by Date (descending)
next pagenext page 1 2 3 ... 12 13 14 ... 29 30 31  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Roche–Davis Polk & Wardwell: legal services, 201902 supply service legal advisor to Roche w regard acquisition of Spark Therapeutics 2019-02-25
Spark Therapeutics–Centerview Partners: financial services, 201902 supply financial advisor to Spark with regard to acquisition of Spark by Roche 2019-02-25
Spark Therapeutics–Cowen: financial services, 201902 supply financial advisor to Spark with regard to acquisition of Spark by Roche 2019-02-25
Spark Therapeutics–Goodwin Procter: legal services, 201902 supply legal counsel to Spark with regard to acquisition of Spark by Roche 2019-02-25
Spark Therapeutics–Roche: investment, 201902–201912 acquisition $4.3b cash tender offer for all shares at $114.5/share 2019-02-25
Alchemist Accelerator–BASF: investment, 201902 BASF Venture Capital invests $2m + becomes Limited Partner 2019-02-20
Calypso Biotech–ABP (NL): investment, 201902 financing round Series A totalling €20m incl co-lead investor Inkef Capital 2019-02-20
Calypso Biotech–Gilde Investment: investment, 201902 financing round Series A totalling €20m incl co-lead investor Gilde Healthcare 2019-02-20
Calypso Biotech–JnJ: investment, 201902 financing round Series A totalling €20m incl co-investor JnJ Innovation JJDC 2019-02-20
Calypso Biotech–Merck (DE): investment, 201902 financing round Series A totalling €20m incl co- + founding investor M Ventures 2019-02-20
Calypso Biotech–SEVERAL: investment, 201902 financing round Series A €20m co-led by Gilde Healthcare + Inkef Capital 2019-02-20
Evotec–Helmholtz: antibiotics, 201902– collab development with initial focus on cystobactamids with Helmholtz HZI Braunschweig 2019-02-20
CRISPR Therapeutics–StrideBio: AAV vectors, 201902– collab expansion €na of developm + license option usingStrideBio’s vectors for CRISPR therapies 2019-02-19
Gain Therapeutics–Fondazione Centenario BancaStato: investment, 201902 financing round Series A totalling €2.5m incl €400k from TiVenture SA 2019-02-19
Gain Therapeutics–Helsinn: investment, 201902 financing round Series A totalling €2.5m incl €1m from new investor Helsinn Investment Fund SA 2019-02-19
Gain Therapeutics–SEVERAL: investment, 201902 financing round Series A €2.5m from VitaTech + Helsinn Investment Fund + TiVenture 2019-02-19
Gain Therapeutics–VitaTech: investment, 201902 financing round Series A totalling €2.5m incl €1.1m from new investor VitaTech SA 2019-02-19
Qiagen–Curetis: bioinformatics, 201902– license excl to use ARESdb for general bioinformatics research offerings + services for AMR research 2019-02-18
S-Biomedic–DSM: investment, 201902 financing round Series A 2nd closing totalling €2m incl new investor DSM Venturing 2019-02-18
S-Biomedic–SEVERAL: investment, 201902 financing round Series A 2nd closing €2m from new investor DSM Venturing + existing investor investiere.ch 2019-02-18
S-Biomedic–Verve Capital Partners: investment, 201902 financing round Series A 2nd closing totalling €2m incl existing investor investiere.ch 2019-02-18
Arvelle Therapeutics–Andera Partners: investment, 201902 financing round Series A totalling $180m incl investor Andera Partners 2019-02-14
Arvelle Therapeutics–BRV Capital: investment, 201902 financing round Series A totalling $180m incl investor BRV Capital Management 2019-02-14
Arvelle Therapeutics–H.I.G. Capital: investment, 201902 financing round Series A totalling $180m incl investor H.I.G. BioHealth Partners 2019-02-14
Arvelle Therapeutics–Life Sciences Partners: investment, 201902 financing round Series A totalling $180m incl lead investor LSP 2019-02-14
Arvelle Therapeutics–NovaQuest Capital: investment, 201902 financing round Series A totalling $180m incl investor NovaQuest Capital Management 2019-02-14
Arvelle Therapeutics–Sam Brown: public relations, 201902 service existent by Sam Brown Inc 2019-02-14
Arvelle Therapeutics–SEVERAL: investment, 201902 financing round Series A $180m with global investor syndicate 2019-02-14
Arvelle Therapeutics–SK Group: cenobamate, 201902– license excl for Europe $110m upfront + $430m milestones + royalties from SK Biopharmaceuticals 2019-02-14
Novartis–AbCellera: therapeutic antibodies, 201902– collab discovery use of AbCellera technology + screening for up to ten targets 2019-02-14
Plasmion–Bavaria (govt): investment, 201902 financing round totalling almost €1m from HTGF + BayBG + business angel 2019-02-14
Plasmion–High-Tech Gründerfonds: investment, 201902 financing round totalling almost €1m from HTGF + BayBG + business angel 2019-02-14
Plasmion–PERSON: investment, 201902 financing round totalling almost €1m from HTGF + BayBG + business angel 2019-02-14
Plasmion–SEVERAL: investment, 201902 financing round almost €1m from HTGF + BayBG + business angel 2019-02-14
Boehringer–IBM: blockchain technology, 201902– collab to integrate blockchain technology into clinical trials of BI Canada + IBM Canada 2019-02-12
Andrew Alliance–Sartorius: electronic pipettes, 201902 collab co-developm + launch Pipette+ system combining Picus hardware with OneLab s/w 2019-02-08
Symrise–SEVERAL: investment, 201902 capital increase €400m with 5.614m new shares at €71.25/share to fund acquisition of ADF/IDF 2019-02-08
Galapagos–Evotec: antifibrotic, 201902– collab + ww commercial rights for Galapagos to small-molecule programme for fibrotic diseases 2019-02-07
Denothex–Optimapharm: investment, 201902 acquisition of Denothex Ltd by Optimapharm 2019-02-06
Waters–Andrew Alliance: automated liquid handling technology, 201902–collab new solutions for LC-MS research 2019-02-06
Bruker–Genedata: bioinformatics, 201902 collab product integration Bruker new Ready-to-Run partner 2019-02-05
Numares–Mayo Clinic: NMR spectroscopy, 201902– collab developm metabolomics-based NMR clinical tests with Mayo Clinic Labs 2019-02-05
Roche–Xencor: cancer immunotherapy, 201901– collab developm + commerc ww $120m upfront + milestones + profit share IL-15 cytokine drugs Genentech 2019-02-05
Macherey-Nagel–Andrew Alliance: automated liquid handling technology, 201902–collab co-marketing NucleoBond kits with OneLab s/w + Andrew+ robot 2019-02-04
United Kingdom (govt)–Qiagen: bioinformatics, 201902– supply Genomics England selects QCI for genome sequencing project of NHS 2019-02-04
ADF/IDF–Symrise: investment, 201901– acquisition $900m by Symrise ANNOUNCED 2019-01-31
Apceth–Hitachi: investment, 201901–201904 acquisition €75.5m 100% of Apceth Biopharma GmbH from Apceth GmbH by Hitachi Chemical 2019-01-31
Bayer–Univ Kyoto: drug discovery, 201901– collab €na research alliance for drug target discovery for pulmonary diseases incl IPF 2019-01-31
Dewpoint Therapeutics–6 Dimensions Capital: investment, 201901 financing round Series A totalling $60m incl co-investor 6 Dimensions Capital 2019-01-30
Dewpoint Therapeutics–Alexandria Real Estate: investment, 201901 financing round Series A totalling $60m incl co-investor Alexandria Ventures 2019-01-30
Dewpoint Therapeutics–Bayer: investment, 201901 financing round Series A totalling $60m incl co-investor Leaps by Bayer 2019-01-30
Dewpoint Therapeutics–EcoR1 Capital: investment, 201901 financing round Series A totalling $60m incl co-investor EcoR1 Capital 2019-01-30
Dewpoint Therapeutics–Polaris Partners: investment, 201901 financing round Series A totalling $60m incl lead investor Polaris Partners 2019-01-30
Dewpoint Therapeutics–Samsara BioCapital: investment, 201901 financing round Series A totalling $60m incl co-investor Samsara BioCapital 2019-01-30
Dewpoint Therapeutics–SEVERAL: investment, 201901 financing round Series A $60m led by Polaris Partners 2019-01-30
Medizinsches Labor Hannover–Labor Limbach: investment, 201901 acquisition 100% of MLH by Limbach Gruppe SE PENDING 2019-01-26
MAB Discovery–BioNTech: investment, 201901–201903 acquisition €na of Antibody Generation Unit of MAB Discovery by BioNTech 2019-01-23
CRISPR Therapeutics–Minapharm: gene transfer technology, 201901– collab + license €na with ProBioGen to develop in vivo delivery technology for CRISPR 2019-01-22
Scailyte–SEVERAL: investment, 201901 seed financing round CHF2.75m incl new investors Swisscom Ventures + Zürcher Kantonalbank 2019-01-22
Scailyte–Swisscom: investment, 201901 seed financing round totalling CHF2.75m incl new investors Swisscom Ventures + Zürcher Kantonalbank 2019-01-22
Scailyte–Zürcher Kantonalbank: investment, 201901 seed financing round totalling CHF2.75m incl new investors Swisscom Ventures + Zürcher Kantonalbank 2019-01-22
Link Health–Marinomed: drug delivery technology, 201901– collab registration + distribution of Marinosolv products in China by Link Health 2019-01-21
Medison Pharma–Alnylam: RNAi therapeutics, 201901– commcercialisation excl of Onpattro + other RNAi drugs from Alnylam in Israel 2019-01-21
Miltenyi Biotec–Univ Duisburg-Essen: imaging technology, 201901 acquisition process for opitcal clearing of biological samples for miccrosopy 2019-01-17
Mologen–SEVERAL: credit, 201901–202701 convertible bonds €2.7m at 6% incl existing shareholders 2019-01-17
Mecuris–Bavaria (govt): investment, 201901 financing round Series A totalling €3.6m incl existing investor Bayern Kapital GmbH 2019-01-16
Mecuris–High-Tech Gründerfonds: investment, 201901 financing round Series A totalling €3.6m incl existing investor HTGF 2019-01-16
Mecuris–Mulcan: investment, 201901 financing round Series A totalling €3.6m incl new investor MII Mulcan International Investments GmbH 2019-01-16
Mecuris–OTHER: investment, 201901 financing round Series A totalling €3.6m incl new investor one of largest German hospital chains 2019-01-16
Mecuris–SEVERAL: investment, 201901 financing round Series A €3.6m incl Bayern Kapital + HTGF + Vesalius Biocapital + Mulcan et al. 2019-01-16
Mecuris–Vesalius Biocapital: investment, 201901 financing round Series A totalling €3.6m incl new investor Vesalius Biocapital III SICAR 2019-01-16
United States (govt)–Valneva: Japanese encephalitis vaccine, 201901– supply $59m+$11m of Ixiaro to US DoD 2019-01-16
Boehringer–Bioharmony Therapeutics: antibiotics, 201901– collab developm of bateriophage lysins 2019-01-15
InterAx Biotech–Falcon III Ventures: investment, 201901 financing round totalling CHF3m incl co-lead investor Falcon III Ventures 2019-01-15
InterAx Biotech–SEVERAL: investment, 201901 financing round CHF3m led by Falcon III Ventures + Investiere 2019-01-15
InterAx Biotech–Verve Capital Partners: investment, 201901 financing round totalling CHF3m incl co-lead investor Investiere 2019-01-15
Cell Signaling Technology–Omni Life Science: cell research instruments, 201901– distribution of OLS’ CERO + CESY instruments by Bioké in Benelux 2019-01-14
Merck (DE)–Roche: biochemical reagents, 201901–2025 distribution extension ww excl of Roche biochemical reagents portfolio 2019-01-14
Agenus–JSR Corp: cell line development, 201901– collab expansion license to use Selexis’ SUREtechnology for production of therapeutic proteins 2019-01-09
BC Platforms–MedEngine (FI): medical data science services, 201901– collab strategic partnership to provide solutions for pharma + health sectors 2019-01-09
Denali Therapeutics–Sirion Biotech: gene delivery technology, 201901– license + collab develop AAV vectors for CNS diseases that could cross BBB 2019-01-09
CureVac–Global Health PR: public relations, 201809 service existent media relations by Global Health PR 2019-01-08
Exscientia–Evotec: investment, 201901 financing round Series B totalling $26m incl $6m from existing investor Evotec AG 2019-01-07
Exscientia–GT Healthcare Capital Partners: investment, 201901 financing round Series B totalling $26m incl new investor GT Healthcare Capital Partners 2019-01-07
Exscientia–SEVERAL: investment, 201901 financing round Series B $26m incl Celgene Corp + GT Heallthcare Capital Partners + Evotec 2019-01-07
F2G Ltd–Optimum Strategic Communications: public relations, 201901 service existent by Optimum 2019-01-07
Immunic–SEVERAL: investment, 201901–201904 financing round €26.7m in connection with reverse merger to list on Nasdaq 2019-01-07
Immunic–Vital Therapeutics: investment, 201901–201904 reverse merger to list on Nasdaq with Vital Therapies renamed Immunic Inc 2019-01-07
Loxo Oncology–Lilly: investment, 201901–201902 acquisition cash tender offer $8b for $235/share 2019-01-07
N-of-One–Qiagen: investment, 201901 acquisition €na of N-of-One Inc by Qiagen 2019-01-07
Roche–Exscientia: drug discovery software, 201901– collab up to CHF67m + royalties using Centaur Chemist to design drug candidates 2019-01-07
Biogen–C4 Therapeutics: neurological drugs, 201901– collab strategic up to $415m upfront/milestones discovery small molecues for protein degradation 2019-01-04
Biogen–Skyhawk Therapeutics: neurological drugs, 201901– collab strategic $74m upfront + milestones discovery small molecues using SkySTAR platform 2019-01-04
Medigene–Helmholtz: cell therapy, 201901– license to co-stimulator to enhance TCR therapies for solid tumours from HMGU 2019-01-04
Ribon Therapeutics–Celgene: investment, 201901 financing round Series B totalling $65m incl new + co-investor Celgene Corp 2019-01-04
Ribon Therapeutics–Column Group: investment, 201901 financing round Series B totalling $65m incl existing + co-investor The Column Group 2019-01-04
Ribon Therapeutics–Deerfield: investment, 201901 financing round Series B totalling $65m incl existing + co-investor Deerfield Management 2019-01-04
Ribon Therapeutics–Euclidean Capital: investment, 201901 financing round Series B totalling $65m incl existing + co-investor Euclidean Capital 2019-01-04
Ribon Therapeutics–JnJ: investment, 201901 financing round Series B totalling $65m incl new + co-investorJJDC 2019-01-04
Ribon Therapeutics–Novartis: investment, 201901 financing round Series B totalling $65m incl new + lead investor Novartis Venture Fund 2019-01-04
next pagenext page 1 2 3 ... 12 13 14 ... 29 30 31  next pagenext page



Advertisement

Picture EBD Group Connector Personal Networking in Life Sciences 650x80

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture [iito] Made Without Love 650x80px

» top